POTENTIAL PROBLEMS IN GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS: SYSTEMATIC REVIEW
DOI:
https://doi.org/10.22159/ijap.2025.v17s2.11Keywords:
Generic Substitution, Epilepsy, Seizure Frequency, Adverse Events, BioequivalenceAbstract
This research aims to identify potential problems arising from substituting generic Antiepileptic Drugs (AEDs). The systematic review utilized databases including PubMed, Science Direct, Google Scholar, ProQuest, and Scopus. Search keywords encompassed (Epilepsy OR “Seizure Disorder” OR Aura) and (“Drug Substitution” OR “Therapeutic Substitutions” OR “Drug Switching” OR “Generic Substitution” OR “Generic Substitutions”) and (Brand). The inclusion criteria were all journals related to generic substitution of AEDs, research journals published from May 2015 to March 2022, and potential problems related to the bioequivalence of generic antiepileptic drugs and clinical outcomes therapy in epilepsy patients after generic substitution of antiepileptic drugs. Clinical outcomes can be seizure frequency, Adverse Events (AEs), Quality of Life (QoL), electroencephalogram (EEG) examination, laboratory evaluation, switchback rate, and emergency room visits. A total of 1,010 articles were identified, and 15 full-text articles were included for analysis. Most studies found no significant differences in seizure frequency, AEs, EEG findings, or laboratory results before and after substitution. Moreover, generic substitution did not adversely affect QoL. Although a small percentage of patients reverted to branded drugs, the switchback rate was minimal, and no notable increase in emergency room visits was reported. Overall, the substitution of generic AEDs is clinically safe and effective, with no significant impact on patient outcomes.
References
WHO. Epilepsy a public health imperative. World Health Organization; 2019. p. 1-12.
Kwan P, Palmini A. Association between switching antiepileptic drug products and healthcare utilization: a systematic review. Epilepsy Behav. 2017;73:166-72. doi: 10.1016/j.yebeh.2017.05.010, PMID 28641169.
Lee G, Jung DS. Brand name to generic substitution of levetiracetam in patients with epilepsy. Seizure Eur J Epilepsy. 2018;60:127-31.
Demina NB, Bakhrushina EO, Anurova MN, Merkushova AG, Pomytkina MV, Rastopchina OV. Complex generics as a trend of modern pharmaceutical development. Int J Appl Pharm. 2024;16(3):71-7.
Trimboli M, Russo E, Mumoli L, Tripepi G, Fortunato F, Mastroianni G. Brand-to-generic levetiracetam switching: a 4 y prospective observational real-life study. Eur J Neurol. 2018;25(4):666-71. doi: 10.1111/ene.13568, PMID 29322654.
Elmer S, Reddy DS. Minireview therapeutic basis of generic substitution of antiseizure medications (May); 2022. p. 188-96.
Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. Springerplus. 2016;5:182. doi: 10.1186/s40064-016-1824-2, PMID 27026878.
Hansen RA, Qian J, Berg R, Linneman J, Seoane Vazquez E, Dutcher SK. Comparison of generic-to-brand switchback rates between generic and authorized generic drugs. Pharmacotherapy. 2017;37(4):429-37. doi: 10.1002/phar.1908, PMID 28152215.
Perucca E. The safety of generic substitution in epilepsy. Lancet Neurol. 2016;15(4):344-5. doi: 10.1016/S1474-4422(16)00042-9, PMID 26875742.
Bosak M, Słowik A, Dziedzic T. Brand-to-generic oxcarbazepine switch-a prospective observational study. Epilepsy Res. 2019;151:75-7. doi: 10.1016/j.eplepsyres.2019.02.017, PMID 30836239.
Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA. Generic lamotrigine versus brand-name lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia. 2015;56(9):1415-24. doi: 10.1111/epi.13095, PMID 26201987.
Polard E, Nowak E, Happe A, Biraben A, Oger E. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Pharmacoepidemiol Drug Saf. 2015;24(11):1161-9. doi: 10.1002/pds.3879.
Bosak M, Słowik A, Turaj W. Safety of switching from brand-name to generic levetiracetam in patients with epilepsy. Drug Des Dev Ther. 2017;11:2287-91. doi: 10.2147/DDDT.S138270, PMID 28814836.
Fanella M, Morano A, Fattouch J, Albini M, Basili LM, Casciato S. Switch from originator to equivalent drug in the era of generic antiepileptic drugs: study of Keppra versus Epitiram clinical equivalence. Clin Neuropharmacol. 2017;40(6):239-42. doi: 10.1097/WNF.0000000000000250, PMID 28976412.
Reimers A, Olsson P, Nilsson J, Hoff E, Reis M, Strandberg M. Impact of generic substitution on levetiracetam serum concentration-a prospective study in an outpatient setting. Epilepsy Res. 2017;134:54-61. doi: 10.1016/j.eplepsyres.2017.04.017, PMID 28595756.
Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP. Bioequivalence between generic and branded lamotrigine in people with epilepsy: the equigen randomized clinical trial. JAMA Neurol. 2017;74(8):919-26. doi: 10.1001/jamaneurol.2017.0497, PMID 28654954.
Markoula S, Chatzistefanidis D, Gatzonis S, Siatouni A, Siarava E, Verentzioti A. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. Seizure. 2017;48:1-6. doi: 10.1016/j.seizure.2017.03.012, PMID 28363098.
Lang JD, Kostev K, Onugoren MD, Gollwitzer S, Graf W, Müller T. Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in germany. Ann Neurol. 2018;84(6):918-25. doi: 10.1002/ana.25353, PMID 30298621.
Olsson P, Reimers A, Kallen K. Quality of life after switching to generic levetiracetam-a prospective comparative study. Epilepsy Behav. 2019;96:169-74. doi: 10.1016/j.yebeh.2019.04.029, PMID 31150996.
Lang JD, Kostev K, Reindl C, Mueller TM, Stritzelberger J, Gollwitzer S. Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: a nationwide study of prescription data in germany. Epilepsy Behav. 2021;115:107705. doi: 10.1016/j.yebeh.2020.107705, PMID 33444987.
Tharavichitkun J, Yadee T, Angkaow P, Suansanae T. Evaluating therapeutic equivalence of generic and original levetiracetam in patients with epilepsy: a retrospective study. Neurol Int. 2022;14(1):271-83. doi: 10.3390/neurolint14010022, PMID 35324578.
Tiamkao S, Kanchanauthai N, Sawanyawisuth K, Tiamkao S. Brand-to-generic levetiracetam switch in patients with epilepsy: seizure control and its predictors in a real-world setting. Open Access Maced J Med Sci. 2022;10(B):1068-71. doi: 10.3889/oamjms.2022.8837.
Critical Appraisal Skills Programme. CASP Checklist: Cohort Studies; 2024. p. 1-6. Available from: https://casp-uk.net/casp-checklists/CASP-checklist-cohort-study-2024.pdf. [Last accessed on 09 Apr 2025].
Critical Appraisal Skills Programme. CASP checklist for randomised controlled trial (RCT); 2024. p. 1–6. Available from: https://casp-uk.net/casp-checklists/CASP-checklist-randomised-controlled-trials-RCT-2024.pdf. [Last accessed on 09 Apr 2025].
Gozzo L, Caraci F, Drago F. Bioequivalence, drugs with narrow therapeutic index and the phenomenon of biocreep: a critical analysis of the system for generic substitution. Healthcare (Basel). 2022;10(8):1392. doi: 10.3390/healthcare10081392, PMID 35893214.
Sowmya C, Abrar AH, Suriya Prakaash KK. Virtual bioequivalence in pharmaceuticals: current status and future prospects. Int J Appl Pharm. 2023;15(5):1-9.
Julian P. Understanding the therapeutic index of antiepileptic drugs. Ann Clin Trials Vaccines Res. 2024:136158(3):140.
Xavier E, George IM, Jacob J, George DL. Assessment of role of FRIDs and PIMS in medication related fall in geriatric population. Int J Pharm Pharm Sci. 2023;5(2):39-44. doi: 10.33545/26647222.2023.v5.i2a.42.
Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48(3):464-9. doi: 10.1111/j.1528-1167.2007.01007.x, PMID 17346246.
Chaluvadi S, Chiang S, Tran L, Goldsmith CE, Friedman DE. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia. 2011;52(4):810-5. doi: 10.1111/j.1528-1167.2011.03025.x, PMID 21426334.
Duh MS, Paradis PE, Latremouille Viau D, Greenberg PE, Lee SP, Durkin MB. The risks and costs of multiple-generic substitution of topiramate. Neurology. 2009;72(24):2122-9. doi: 10.1212/WNL.0b013e3181aa5300, PMID 19528520.
Becker DA, Wheless JW, Sirven J, Tatum WO, Rabinowicz AL, Carrazana E. Treatment of seizure clusters in epilepsy: a narrative review on rescue therapies. Neurol Ther. 2023;12(5):1439-55. doi: 10.1007/s40120-023-00515-3, PMID 37341903.
Vossler DG, Anderson GD, Bainbridge J. AES position statement on generic substitution of antiepileptic drugs. Epilepsy Curr. 2016;16(3):209-11. doi: 10.5698/1535-7511-16.3.209, PMID 27330454.
Kumala Swandari MT, Karuniawati H, Cholisoh Z. The influence of medication therapy management (Mtm) on clinical outcomes and treatment compliance in diabetes mellitus patients: a systematic review. Int J Appl Pharm. 2024;16 Special Issue 5:18-24.
Karuniawati H, Ikawati Z, Gofir A. Adherence to secondary stroke prevention therapies in ischemic stroke patients at teaching hospital in Central Java Indonesia. Asian J Pharm Clin Res. 2017;10(14) Special Issue:28-30. doi: 10.22159/ajpcr.2017.v10s2.19478.
Karuniawati H, Putra On, Wikantyasning ER. Impact of pharmacist counseling and leaflet on the adherence of pulmonary tuberculosis patients in lungs hospital in Indonesia. Indian J Tuberc. 2019;66(3):364-9. doi: 10.1016/j.ijtb.2019.02.015, PMID 31439181.
Moya Salazar J, Ananca G, Goicochea EA, Rojas Zumaran V, Moya Salazar B, Contreras Pulache H. The severity of adverse events is associated with the age of hospitalized patients: a retrospective study. TONURSJ. 2023;17(1):1-6. doi: 10.2174/18744346-v17-230403-2022-154.
Incecik F, Herguner MO, Altunbasak S. The efficacy and side effects of levetiracetam on refractory epilepsy in children. J Pediatr Neurosci. 2012;7(1):19-22. doi: 10.4103/1817-1745.97614, PMID 22837771.
Tao K, Chen H, Chen Y, Gu Y, Wang X. Levetiracetam induces severe psychiatric symptoms in people with epilepsy. Seizure. 2024;116:147-50. doi: 10.1016/j.seizure.2022.12.002, PMID 36535885.
Sharma J, Sharma A, Singh S. Comparative analysis of Stevens-Johnson syndrome incidence among seizure patients on different antiepileptic drugs. Asian J Pharm Clin Res. 2024;17(12):232-5.
Michaelis R, Tang V, Goldstein LH, Reuber M, LaFrance WC, Lundgren T. Psychological treatments for adults and children with epilepsy: evidence-based recommendations by the International League Against Epilepsy Psychology Task Force. Epilepsia. 2018;59(7):1282-302. doi: 10.1111/epi.14444, PMID 29917225.
Pinasthika S, Nugraheni AY. Evaluation of the quality of pharmaceutical care and identification of human resources and infrastructure in the pharmacy installation of hospital in Sukoharjo in 2023. Pharmacon J Farm Indones. 2024;21(1):77-89.
Hasan TF, Tatum WO. When should we obtain a routine EEG while managing people with epilepsy? Epilepsy Behav Rep. 2021;16:100454. doi: 10.1016/j.ebr.2021.100454, PMID 34041475.
Jin SJ, Lee T, Moon HE, Park ES, Lee SH, Roh YI. Classification model for epileptic seizure using simple postictal laboratory indices. J Clin Med. 2023;12(12):4031. doi: 10.3390/jcm12124031, PMID 37373723.
Published
How to Cite
Issue
Section
Copyright (c) 2025 MEILANI ., BURHANNUDIN ICHSAN
This work is licensed under a Creative Commons Attribution 4.0 International License.
